Oxytocin: What It Is, Where to Get It Prescribed, and What It Costs

Oxytocin is a nine-amino-acid peptide hormone, sequence CYIQNCPLG with a disulfide bridge between the two cysteines. It is made in the hypothalamus and released from the posterior pituitary into the bloodstream, and also within the brain, where it acts on oxytocin receptors in regions involved in social behaviour. Its physiology is among the best characterised of any peptide: it drives uterine contractions in labour, triggers milk ejection during breastfeeding, and is released during sexual activity. A 1987 paper in the Journal of Clinical Endocrinology and Metabolism measured plasma oxytocin rising during arousal and peaking around orgasm in both sexes, which is the observation the intimacy use is built on.

Unlike most peptides on this site, oxytocin is not a research compound. It has been an approved hospital drug for decades; the compounded version is the same molecule at a different concentration for a different route and purpose.

The name comes from the Greek for "swift birth." The "bonding hormone" label came much later, from animal research — mostly in prairie voles, a monogamous rodent — showing that oxytocin signalling in the brain was necessary for pair-bonding and maternal behaviour; a 2009 review in Frontiers in Neuroendocrinology covers that literature. The popular name overstates what is known in people, and this page tries not to.

It is not a hormone replacement; there is no accepted "oxytocin deficiency" diagnosis in adults. It is not a treatment for erectile dysfunction — the couples trial below reported no effect on erection or lubrication. It is not a libido drug in the sense that PT-141 is; the trials describe effects on the experience of intimacy, not on desire. And it is not a psychiatric medication, despite a large literature testing it in psychiatric conditions.

Oxytocin binds a single G-protein-coupled receptor found on uterine smooth muscle, the myoepithelial cells of the breast, and tissues throughout the reproductive tract in both sexes. Activation causes smooth-muscle contraction — the mechanism behind the approved obstetric uses and the rhythmic contractions of orgasm.

Oxytocin neurons project into the amygdala, nucleus accumbens and prefrontal cortex. In animals, signalling there is described as reducing the amygdala's response to social threat and increasing the reward value of social contact; the vole pair-bonding work sits on this pathway. In humans, the modern literature began with a 2005 study in Nature reporting that a 24 IU intranasal dose increased trust in an economic game; many behavioural studies followed, and a good number did not replicate at the same size in larger samples. Whether a dose given to a human reaches these brain regions in meaningful concentration is an open question — see "The delivery problem."

The 2008 Psychoneuroendocrinology study in healthy men found intranasal oxytocin raised epinephrine during sexual activity without changing cortisol, and the 2014 couples study found cortisol, alpha-amylase and heart rate unaffected. The "reduces stress" description seen elsewhere is not supported by those measurements; what the intimacy trials describe is a subjective effect, not a hormonal one.

Oxytocin has a plasma half-life of a few minutes and crosses the blood–brain barrier poorly. A 2016 paper in Biological Psychiatry, "Intranasal Oxytocin: Myths and Delusions," argued that the amount of sprayed oxytocin reaching the brain is uncertain and many reported effects may be peripheral or placebo; a statistical critique in the same journal that year found most studies too small to detect the effects they claimed. Those critiques apply at least as strongly to an injection, which has no nose-to-brain pathway. The peripheral effects are certain; the central effects of an exogenous dose in adults are plausible but unproven.

The one indication where the evidence is not in doubt: oxytocin injection has been used to induce and augment labour and control postpartum bleeding for generations. None of this transfers to the intimacy use; it is mentioned so the strength of the evidence is not confused across indications.

The best study is a 2014 paper in Hormones and Behavior: 29 healthy heterosexual couples given 24 IU intranasal oxytocin or placebo in a double-blind crossover and assessed after intercourse at home. Oxytocin did not change sexual drive, arousal, erection or lubrication. What it did change was orgasm intensity and contentment after intercourse, with men reporting higher sexual satiety and women feeling more relaxed and, in subgroups, better able to share sexual desires and empathise with their partner. The authors described the effect sizes as small to moderate.

A 2008 Psychoneuroendocrinology study in ten healthy men found no change in appetitive, consummatory or refractory sexual behaviour on the scale used, though eight of ten could correctly guess when they had received oxytocin.

On the negative side, a 2015 randomised crossover trial in Fertility and Sterility gave 30 pre- and postmenopausal women with sexual dysfunction 32 IU intranasal oxytocin or placebo before intercourse for eight weeks each. Both groups improved substantially on the Female Sexual Function Index and on distress and quality-of-life scales, with no significant difference between oxytocin and placebo. This is the largest trial in women with an actual diagnosis, and it was null.

The 2008 Journal of Sexual Medicine paper is a single case report: one man with treatment-resistant acquired anorgasmia, given intranasal oxytocin during intercourse, with ejaculation reported as restored. It is the origin of the "before intimacy" timing on compounded prescriptions. It is one patient, not a trial.

A 2009 randomised, placebo-controlled trial in Psychoneuroendocrinology gave 24 IU oxytocin or placebo alongside exposure therapy to 25 people with social anxiety disorder. Participants on oxytocin rated their own appearance and speech performance more positively, but overall symptom reduction was the same in both groups.

The largest body of controlled data, and the clearest lesson in why small trials mislead. A 2016 crossover trial in Molecular Psychiatry in 31 young children reported improved caregiver-rated social responsiveness; a 2017 meta-analysis in Pharmacopsychiatry found the pooled evidence weak. Then in 2021 the New England Journal of Medicine published SOARS-B: 290 children and adolescents, 24 weeks, placebo-controlled. The change on the primary social-withdrawal measure was −3.7 with oxytocin and −3.5 with placebo. Pepti does not prescribe for autism; the trial is here because it is the best-powered test of whether exogenous oxytocin changes social behaviour in humans, and the answer was no.

Unusually for a compounded peptide, there is a great deal, pointing in more than one direction. Randomised, placebo-controlled human trials of oxytocin exist, in couples, women with sexual dysfunction, people with social anxiety and children with autism. The strongest positive finding for intimacy is the 2014 couples study; the strongest negative is the 2015 women's trial, where oxytocin did no better than placebo; the largest trial of any kind, SOARS-B, was null.

Every one of those trials used the intranasal route; there are no randomised trials of subcutaneous oxytocin for intimacy, mood or social function. The compounded injection is prescribed on the basis of the intranasal literature plus clinical experience, and the nasal route may have brain-delivery properties an injection does not. A 2021 review in Molecular Psychiatry from the field's own researchers acknowledged that early studies were underpowered and that dosing, delivery and who responds are still being worked out.

• It does not establish that oxytocin increases sexual desire or arousal. The couples trial found no effect on those; the women's trial found no effect over placebo on anything.
• It does not establish that oxytocin treats anxiety, depression or relationship problems.
• It does not establish that a subcutaneous dose reproduces intranasal findings. That study has not been run.
• It does not establish an effect size or response rate in prescribed patients; the reported effects are from healthy volunteers.
• It does not establish long-term safety of repeated non-obstetric use over years. The longest controlled exposure is 24 weeks.

Oxytocin is fast and short. Plasma levels rise within minutes of a subcutaneous injection and clear with a half-life of a few minutes, which is why the directions time it 30 to 60 minutes before intimacy and dose it as needed rather than daily. Whatever effect a dose has is confined to that window; nothing accumulates.

Prescribers generally describe patients either noticing something in the first two or three uses — feeling more relaxed, more present with a partner, or a more intense orgasm — or not noticing anything. This matches the couples trial, where effects were on the experience around and after orgasm rather than on getting there. Noticing nothing is common; report it to your physician rather than escalating on your own.

A vial is 50 doses. At a few uses a week that is roughly ten weeks, enough time to know whether it is doing anything for you. The women's trial found both oxytocin and placebo groups improving over eight weeks — a reminder that attending to intimacy on a schedule may itself be part of what people report.

No withdrawal, rebound or suppression of your own oxytocin is described in the literature. Each dose clears in minutes, so stopping simply means the next intimate occasion is unmedicated.

The directions are written in millilitres and insulin-syringe units because that is what you can read off the barrel. 0.10 mL is 10 units on a U-100 syringe. This is a syringe-volume unit, not a USP unit of oxytocin — the hospital product is labelled in USP units of activity, the compounded vial in milligrams per millilitre, and the two are not interchangeable. The number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated. The 30-to-60-minute timing reflects the short half-life: inject too early and the dose is gone before it matters. "As needed" means exactly that — not a daily medication, no loading period.

50 doses at the standard volume. Because use is as needed, the "about 10 weeks" figure assumes roughly five uses a week; at fewer, a vial lasts longer, subject to the beyond-use date on the label. One vial per fill, always.

Refrigerated, and it ships that way in insulated packaging with ice packs. Heat degrades oxytocin, so it goes back in the fridge after each draw. Beyond-use dating runs from first puncture and is on the label. There is no pen format; it is vial and syringe only.

Different targets and different jobs. PT-141 (bremelanotide) is a melanocortin-receptor agonist acting on desire and arousal pathways, with randomised trials in hypoactive sexual desire disorder behind it and a more prominent side-effect profile (nausea, flushing, transient blood-pressure rise). Oxytocin's trial evidence is about orgasm intensity, post-intercourse contentment and partner interaction, not desire. They are complementary rather than competing, which is why the PT-141 + Oxytocin preparation exists.

Kisspeptin works upstream, stimulating the hormone axis that governs testosterone and estrogen production; oxytocin has no effect on reproductive hormone output. If the picture is hormonal, kisspeptin is the closer fit; if hormones are normal and the problem is the intimate experience itself, oxytocin is the more direct conversation.

Same molecule, different product. Pitocin is 10 USP units/mL for IV or IM use in a hospital, with obstetric indications. The compounded vial is 2 mg/mL for subcutaneous self-injection, off-label, at a fraction of an obstetric dose. The approval covers the hospital product, not the compounded one.